MONASH IVF GROUP

Invest in life

Annual General Meeting 24 November 2017

Disclaimer

The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) ("MVF") (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF's activities as at the date of this presentation. The information does not purport to be complete, is given in summary and may change without notice.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate. The presentation does not constitute or form part of an offer to buy or sell MVF securities.

This presentation contains forward looking statements, including statements of current intention, statements of opinion and predictions as to possible future events. Such statements are not statements of fact and there can be no certainty of outcome in relation to the matters to which the statements relate. These forward looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual outcomes to be materially different from the events or results expressed or implied by such statements. Those risks, uncertainties, assumptions and other important factors that could cause the actual outcomes to be materially different from the events are not all within the control of MVF and cannot be predicted by MVF and include changes in circumstances or events that may cause objectives to change as well as risks, circumstances and events specific to the industry, countries and markets in which MVF operate. They also include general economic conditions, exchange rates, interest rates, the regulatory environment, competitive pressures, selling price, market demand and conditions in the financial markets which may cause objectives to change or may cause outcomes not to be realised.

None of MVF (and their respective officers, employees or agents) (the **Relevant Persons**) makes any representation, assurance or guarantee as to the accuracy or likelihood of fulfilment of any forward looking statement or any outcomes expressed or implied in any forward looking statements. The forward looking statements in this presentation reflect views held only at the date of this presentation. Except as required by applicable law or the ASX Listing Rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any forward looking statements, whether as a result of new information or future events. Statements about past performance are not necessarily indicative of future performance.

Certain jurisdictions may restrict the release, publication or distribution of this presentation. Persons in such jurisdictions should observe such restrictions. To the extent permitted by law the Relevant Persons do not accept liability for any use of this presentation, its contents or anything arising in connection thereto including any liability arising from the fault or negligence none of the Relevant Persons.



Key Achievements

- ✓ Focus on developing industry leading science & technology
- ✓ Strategic positioning as the leading premium service provider
- ✓ Earnings increase despite decline in Patient Treatments
- KL Fertility in Malaysia continues growth trajectory Investment to support
- Market share only declined marginally in a competitive market
- Committed to our premium service offering strategy with rebranding of low intervention clinic to premium full service
- ✓ Diversification through women's imaging expansion
- ✓ Successful launch of Non Invasive Prenatal Test
- ✓ Exploring growth opportunities domestically & abroad





FY2018 Trading Update

- Australian stimulated cycles market increased by 4.3% in the first quarter predominately from low-cost IVF sector that we strategically don't participate in
- Our Australian stimulated cycles market share declined by 2.5% in the first quarter representing a 6.6% decline in our Australian stimulated cycles
- We continue to invest in long term sustainable growth through leading science & new technologies, international business development and our people
- Incurred one-off expenditure relating to legal costs and CEO recruitment
- Doctor departure in Victoria with comprehensive plan to provide a smooth transition and continuity of care for our patients. The speed of this transition will impact our 1H18 financial performance

H1FY2018 Outlook

As a result of the factors outlined above, including one-off expenditure, and subject to trading in the remaining months, we anticipate reported NPAT for H1FY18 will be approximately 20% down on the previous corresponding period. Further guidance on the full year earnings will be provided at our half year results announcement.



Thank you

- Senior Management Team
- Our passionate doctors, nurses, scientists and support staff providing superior patient care
- Shareholders for continued support

Welcome

- David Morris Commenced 13/11/17
- Experience in healthcare, international business development and strategy setting & execution






Introduction

- Honoured and excited to join such an innovative company that is at the forefront of fertility treatment.
- Passionate about Life Sciences and Healthcare.
- Energised when I am working for a cause; especially one that changes people's lives.
- Build on our success based on good science and technology, a strong clinic network and talented people with abundant capabilities and deep experience.
- Work together with all our stakeholders to deliver positive patient, clinician and commercial outcomes.
- I look forward to leading Monash IVF Group through its next phase of growth, and to help bring life to the world.





Overview of Monash IVF Group




Monash IVF Group is a market leader in women's health

Track record of strong financial performance






Revenue (\$m)



4 Year CAGR³ of 12.7%

NPAT (\$m)



4 Year CAGR³ of 12.8%

Strong long term growth across all key metrics

Patient Treatments are the sum of stimulated and cancelled cycles and frozen embryo transfers

2 FY14 adjusted to exclude IPO costs and restructuring costs

CAGR is Compound Annual Growth Rate 3.

4.

FY15 earnings were impacted unfavourably by below industry trend growth rates and one off start up & acquisition costs of \$975k (Pre-tax) Earnings before interest, tax, depreciation and amortisation (EBITDA) is a non-IFRS measure which is used by the Group as a key indicator of underlying performance and is not subject to audit or review 5

Monash IVF Group | Annual General Meeting 2017

Financial and Operational Highlights



FY17 Financial Highlights

Revenue \$155.2m

FY16 \$156.6m Down 0.9% on pcp

EBITDA¹ \$49.0m

FY16 \$49.6m Down 1.2% on pcp

Total FY17 Dividend

8.8c

FY16 8.5 cents Up 3.5% on pcp

NPAT

\$29.6m

FY16 \$28.8m Up 2.9% on pcp Cash Conversion²

93.9%

FY16 \$99.1% Down 5.2% on pcp **Basic EPS 12.6c**

FY16 12.2 cents Up 3.3% on pcp

Notes 1.

Earnings before interest, tax, depreciation and amortisation (EBITDA) is a non-IFRS measure which is used by the Group as a key indicator of underlying performance and is not subject to audit or review 2.

Pre-tax conversion of operating cash flow to EBITDA calculated as cash generated from operations divided by EBITDA.


FY2017 Operational Highlights

- Monash IVF's Australian IVF market share only declined marginally in FY17, demonstrating the strength and resilience of its premium offering
- Monash IVF's ultrasound scan volumes declined in FY17
- Strong cost control and efficient work practices limited EBITDA margin erosion (to 10bp)
- Continued investment in science and research demonstrates Monash IVF's commitment to leading edge technology and innovation in the provision of fertility services
- KL Fertility moved to a new, state of the art facility in May 2017 feedback from patients and clinicians is excellent, which is flowing through to strong demand growth
- Conversion and rebranding of "Bump" (Mosman) to a Monash IVF full service site demonstrates our commitment to a premium service offering;
- All Sydney clinics now operate under the Monash IVF brand (compared to three different brands at beginning of FY17)
- Monash IVF brand awareness and consideration has further increased over the last two years



Australian IVF market movement

Stimulated Cycle Growth Rates in Key Markets¹





Source: Medicare Benefit Schedule Item Statistics Reports [13200, 13201], Commonwealth Department of Health and Ageing)

- The Australian IVF Market softened in FY17 against very strong comparative volumes in the pcp
- Total Key Markets¹ Stimulated Cycles increased by 0.2% in FY17 vs pcp (compared to FY16 growth of 6.8% on pcp)
- Total Australian Stimulated Cycles declined by 0.8% in FY17 vs pcp (compared to FY16 growth of 6.8% vs pcp)
- The volatility by quarter in FY17, and the significantly lower growth in FY17 following the period of very high growth in FY16, demonstrates the variable and oscillating nature of IVF market growth rates in the short term


Market growth rate will fluctuate from time to time. We maintain our view that the long term Stimulated Cycles growth rate is expected to be approximately 3% per annum

Notes

1. Based on the combined number of Stimulated Cycles (excluding Cancelled Cycles) in New South Wales, Victoria, South Australia, Queensland and Northern Territory.

0

Australian market share – IVF



 Stimulated Cycle³ market share in Australia decreased by 0.5% to 22.4% vs pcp; Stimulated Cycle market share in Key Markets² decreased by 0.9% to 25.2% vs pcp;


 Patient Treatment¹ market share in Australia decreased by 0.6% to 23.2% vs pcp; Patient Treatments¹ market share in Key Markets² decreased by 0.9% to 26.4% vs pcp

Notes:

- 1. IVF Patient Treatments are the sum of fresh and cancelled cycles and frozen embryo transfers consistent with historical reporting metrics
- 2. Victoria, South Australia, Queensland, Northern Territory and New South Wales
- 3. Stimulated cycles (excluding Cancelled Cycles)



Expanding domestic & brand consolidation



 "MyIVF" medium-cost brand remains part of our strategy to understand the low cost / low intervention non-premium market

International FY17 overview

• KL Fertility

- Continued strong growth in volumes achieved as new fertility specialists continue to gain traction Patient Treatments up 10.1%
- Relocated to state of art new IVF facility in May 2017 signs are very positive, reflected through patient feedback and strong demand growth since opening
- EBITDA⁽¹⁾⁽²⁾ margin increased by 90bp through leverage from incremental volumes
- New dedicated International Business Development Manager is actively reviewing further international growth opportunities

Profit and loss	FY17	FY16	% change
Revenue	\$6.3m	\$6.2m	1.3%
EBITDA ⁽¹⁾⁽²⁾	\$2.5m	\$2.4m	3.3%
EBITDA margin	40.3%	39.4%	90 bp
IVF treatment numbers			
Stimulated cycles	689	617	+11.7%
Cancelled cycles	54	67	(19.4%)
Frozen embryo transfers	603	539	+11.9%
Patient Treatments	1,346	1,223	+10.1%

Notes:

 EBITDA is a non IFRS measure which is used by the Group as a key indicator of underlying performance. This and any other non IFRS measure is not subject to audit and review.

2. EBITDA is earnings before interest, tax, depreciation and amortisation.







Our Brands and Marketing



New Monash IVF website



Social Egg Freezing



Ultrasound marketing



Maximising our digital footprint







FY2018 Trading Update

Australian Stimulated Cycle market grows above long-term growth rate in Q1FY18, driven by low cost IVF sector

- Total Key Market¹ Stimulated Cycles increased by 4.6% in Q1FY18 vs pcp (decline of 2.9% in Q1FY17 vs pcp). Victoria, New South Wales and Queensland grew whilst SA and NT declined
- Monash IVF Group Australia Stimulated Cycles declined by 6.6% vs total Key Market¹ increase of 4.6% in Q1FY18. The decline is a result of market weakness in South Australia, transition of the Mosman, NSW clinic from low cost to premium full service and low cost IVF providers capturing growth, particularly in QLD
- Monash IVF Group frozen embryo transfer (FET) cycles increased by 1.5% vs the total Key Market¹ increase of 9.7% in Q1FY18

Australian Market Share position (Q1FY18)


- Total Australian Stimulated Cycle market share reduced to 21.1% from 23.6% in the pcp
- Monash IVF Group market share in its Key Markets¹ reduced to 23.8% from 26.7% in the pcp
- We experienced market share declines due to competitive pressures in Victoria, Queensland and South Australia whilst New South Wales declined due to transitioning the Mosman clinic from low cost to a premium full service

Stimulated Cycle Growth Rates in Key Markets¹



As previously stated IVF industry growth rates fluctuate from time to time. We maintain our view the long term Stimulated Cycle growth rate is expected to be approximately 3% per annum in the premium full service IVF market.

Note¹: Based on the combined number of Stimulated Cycles in Victoria, South Australia, Queensland, Northern Territory and New South Wales.



FY18 Trading Update - Continued

- KL Fertility in Malaysia is settled in the new, state of the art facility which is flowing through to strong demand growth in Q1FY18
- Complementing MVF's women's imaging services, our investment to inhouse Non Invasive Prenatal Testing (NIPT) is delivering to plan with expected earnings contribution in Q1FY18 ensuring we maintain leading edge science
- To ensure long term sustainability and growth prospects are maximised, we are continuing to invest in:
 - Leading science and new technologies
 - International business development
 - The right human resource and remuneration structures
- Non-recurring expenditure will be absorbed in H1FY18 financials including legal costs regarding a departing clinician in Victoria and recruitment costs of a new CEO.
- As a result of the departing clinician in Victoria a comprehensive plan is being managed to provide a smooth transition and continuity of care for our patients, however the speed of that transition will impact our H1FY18 results.

Invest in life

MONASH IVF GROUP

Annual General Meeting

24 November 2017